Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.37B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.04M
Average 0.08M
NBTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Nanobiotix S.A.NASDAQ: NBTX
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income declines year over year
Q4 FY2025 net income of €18.58M (cash outflow) fell 59.8% year over year. Over 3 fiscal years it compounded at -25.1% a year.
Context
- Net income amounted to 80.8% of revenue in FY2025.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -€25.54M (+6.6%) for the fiscal year ending Dec 2026, a step up from the -64.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -€18.58M— QoQ
- Last fiscal yearDec 2025
- -€23.96M-64.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -59.8% | — | — |
| 1 year | -64.8% | +6.6% | +71.4 pp |
| 3-year CAGR | -25.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
EUR · from the cash flow
- Latest · FY2025
- (23.96M) EUR
- Year-over-year change
- +64.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (23.96M) | +64.8% |
| FY2024 | 2024-12-31 | (68.13M) | -71.6% |
| FY2023 | 2023-12-31 | (39.7M) | +30.4% |
| FY2022 | 2022-12-31 | (57.04M) | -21.4% |
| FY2021 | 2021-12-31 | (47M) | — |
Net Income vs competitors
How NBTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -64.8% is the 10th highest of 11, against a peer median of +36.7%.
- Net income amounts to 80.8% of revenue for NBTX, versus a peer median of 261.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.11B USD | +218.3% | -5.5% | 607.8% | |
| LTM Mar 2026 | $294.57M USD | +62.0% | +27.1% | 411.2% | |
| LTM Mar 2026 | $243.25M USD | -26.6% | +24.1% | 112.0% | |
| LTM Mar 2026 | $145.24M USD | +14.0% | +65.2% | — | |
| LTM Mar 2026 | $131.11M USD | +36.0% | +29.4% | — | |
| LTM Mar 2026 | $54.42M USD | +37.5% | +26.7% | — | |
| LTM Mar 2026 | $43.21M USD | -948.8% | — | — | |
| LTM Mar 2026 | $34.98M USD | +67.3% | +52.9% | — | |
| LTM Mar 2026 | $29.59M USD | +46.8% | +11.5% | — | |
| LTM Mar 2026 | $24.38M USD | -35.9% | +2396.3% | 10.7% | |
| FY2025 | €23.96M EUR | -64.8% | -25.1% | 80.8% | |
| Peer median (excluding NBTX) | — | +36.7% | +27.1% | 261.6% | |
Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47M) | (57.04M) | (39.7M) | (68.13M) | (23.96M) |
| Depreciation & Amortization | 1.56M | 1.5M | 1.51M | 1.62M | 1.5M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 3K |
| Stock-Based Compensation | 3.2M | 3.17M | 3.3M | 4.3M | 3.54M |
| Change in Working Capital | (4.7M) | (606K) | (367K) | 131K | (3.4M) |
| Accounts Receivables | 62K | (101K) | (806K) | (2.07M) | 1.85M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (4.76M) | (505K) | 439K | 2.2M | (5.25M) |
| Other Non-Cash Items | 17.07M | 15.87M | 22.78M | 42.53M | (11.1M) |
| Operating Cash Flow | (29.87M) | (37.1M) | (12.48M) | (19.55M) | (33.42M) |
| Capital Expenditures | (228K) | (92K) | (328K) | (846K) | (546K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (14K) | 230K | (21K) | (109K) | (40K) |
| Investing Cash Flow | (242K) | 138K | (349K) | (955K) | (578K) |
| Debt Repayment | (3.74M) | (4.74M) | (3.62M) | (4.16M) | 38.19M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 1.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.44M) | (916K) | 50.39M | (980K) | (2.31M) |
| Financing Cash Flow | (5.18M) | (5.65M) | 46.77M | (5.14M) | 37.42M |
| Effect of Forex Changes | 64K | 83K | (51K) | 94K | (402K) |
| Net Change in Cash | (35.23M) | (42.53M) | 33.9M | (25.55M) | 3.01M |
| Free Cash Flow | (30.1M) | (37.2M) | (12.8M) | (20.4M) | (33.97M) |
Nanobiotix S.A.
NASDAQ:NBTX
Intrinsic Alpha fair value
Locked
Current Price
$26.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.